A research group in Catalonia (Spain) has developed a new family of proapoptotic compounds for the treatment of cancer. It is a multidisciplinary group with wide experience on the synthesis of new chemical compounds and in the evaluation of proapoptotic compounds. The research group is looking for license agreement, but other collaborations may be considered (e.g. financial resources, etc.).